亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費(fèi)注冊|忘記密碼|管理入口 返回主站||保存桌面|手機(jī)瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

武漢楷倫化學(xué)新材料有限公司市場  

比馬前列素 阿瑞匹坦及中間體 亞硝基過***鉀 埃索美拉唑鈉及中間體 CB-03-1

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
聯(lián)系方式
  • 聯(lián)系人:江君
  • 電話:027-87773372
  • 郵件:2513471628@qq.com
  • QQ:2513471628
站內(nèi)搜索
 
榮譽(yù)資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
奧替拉西鉀
單價 面議對比
詢價 暫無
發(fā)貨 湖北武漢市付款后3天內(nèi)
過期 長期有效
更新 2019-06-28 09:56
 
詳細(xì)信息
 
中文名稱:奧替拉西鉀
中文同義詞:草酰鉀;氧嗪酸鉀;1,4,5,6-四氫-4,6-二氧-1,3,5-三嗪-2-羧酸鉀;4,6-二羥基-1,3,5-噻嗪-2-羧酸鉀鹽;氧嗪酸鉀(OXO);氧氫酸鉀;;氧嗪酸鉀(奧替拉西)
英文名稱:Potassium oxonate
英文同義詞:1,4,5,6-tetrahydro-4,6-dioxo-s-triazine-2-carboxylicacid,potassiumsalt;5-azaoroticacid,potassiumsalt;kox;potassiumazaorotate;POTASSIUM OXONATE;POTASSIUM 4,6-DIHYDROXY-1,3,5-TRIAZINE-2-CARBOXYLATE;Potassium 1,4,5,6-tetrahydro-4,6-dioxo-1,3,5-triazine-2-carboxylate;POTASSIUM ALLANTOXANATE
CAS號: 2207-75-2
分子式: C4H2KN3O4
分子量: 195.17
性狀:白色結(jié)晶粉末
熔點(diǎn):300 °C(lit.)
用途:抗腫瘤及免疫抑制劑;醫(yī)藥中間體
©2025 武漢楷倫化學(xué)新材料有限公司市場 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:10621  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |